Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful Formulation Window for the design of pharmaceutical tablets with required mechanical properties.

International journal of pharmaceutics·2023
Same author

Extracellular vesicles in infectious diseases - importance and perspectives.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne·2023
Same author

Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne·2022
Same author

Management of ileocolic intussusception in the Czech Republic.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2021
Same author

Increasing procoagulant activity of circulating microparticles in patients living with HIV.

Medecine et maladies infectieuses·2019
Same author

Progressive multifocal leukoencephalopathy - epidemiology, immune response, clinical differences, treatment.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne·2019
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

[HIV lipodystrophy].

S Snopková1, M Matýsková, K Povolná

  • 1Klinika infekcních chorob Lékarské fakulty MU a FN Brno. svatava.snopkova@fnbrno.cz

Vnitrni Lekarstvi
|January 26, 2011
PubMed
Summary
This summary is machine-generated.

Combined antiretroviral therapy (cART) significantly improves HIV/AIDS outcomes but can cause HIV lipodystrophy. This syndrome presents metabolic and morphological changes, increasing cardiovascular risk in HIV patients.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Area of Science:

  • Infectious Diseases
  • Cardiovascular Health
  • Metabolic Disorders

Context:

  • Combined antiretroviral therapy (cART) has transformed HIV/AIDS prognosis, reducing morbidity and mortality.
  • Long-term cART use is associated with metabolic and morphological abnormalities, termed HIV lipodystrophy syndrome.
  • HIV lipodystrophy shares features with metabolic syndrome, posing risks for premature atherosclerosis and cardiovascular disease in HIV-positive individuals.

Purpose:

  • To review the relationship between antiretroviral treatment and cardiovascular risk in HIV patients.
  • To discuss the metabolic and morphological changes associated with HIV lipodystrophy.
  • To explore the potential atherogenic risk of HIV lipodystrophy compared to metabolic syndrome in the general population.

Summary:

  • HIV lipodystrophy encompasses dyslipidemia, insulin resistance, and fat redistribution (lipoatrophia or lipohypertrophia).
  • Metabolic changes include hypercholesterolemia, hypertriglyceridemia, hyperinsulinaemia, and hyperlaktataemia.
  • Morphological changes involve subcutaneous fat loss (lipoatrophia) or fat accumulation (lipohypertrophia) in specific body areas.

Impact:

  • HIV lipodystrophy syndrome increases the risk of premature atherosclerosis and cardiovascular events in HIV-infected individuals.
  • Current research on cART and cardiovascular risk is inconclusive due to study length limitations.
  • Uncontrolled HIV infection and low CD4+ counts appear to be major contributors to accelerated atherosclerosis.